Jean Jacques Gonvers

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint Obstructive fibrostenotic Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:29-30. 2005
  2. ncbi request reprint A European view of diagnostic yield and appropriateness of colonoscopy
    Jean Jacques Gonvers
    Division of Gastroenterology and Hepatology, Policlinique Medicale Universitaire, Lausanne, Switerland
    Hepatogastroenterology 54:729-35. 2007
  3. doi request reprint Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study
    Jean Jacques Gonvers
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Swiss Med Wkly 140:w13055. 2010
  4. ncbi request reprint Pregnancy and Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:54-61. 2005
  5. ncbi request reprint Fistulizing Crohn's disease
    Christian Felley
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:26-8. 2005
  6. ncbi request reprint Treatment of gastroduodenal Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:37-40. 2005
  7. ncbi request reprint Treatment of postoperative Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:49-53. 2005
  8. ncbi request reprint Maintenance of remission in Crohn's disease
    Jean Jacques Gonvers
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:41-8. 2005
  9. ncbi request reprint Extraintestinal manifestations of Crohn's disease
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:31-6. 2005
  10. ncbi request reprint Severe and steroid-resistant Crohn's disease
    Pierre Michetti
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:19-25. 2005

Collaborators

Detail Information

Publications48

  1. ncbi request reprint Obstructive fibrostenotic Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:29-30. 2005
    ..Mechanical treatment methods consist of endoscopic balloon dilation, stricturoplasty or surgical resection. Fibrostenotic Crohn's disease does not respond to medical therapy and requires endoscopic or surgical treatment...
  2. ncbi request reprint A European view of diagnostic yield and appropriateness of colonoscopy
    Jean Jacques Gonvers
    Division of Gastroenterology and Hepatology, Policlinique Medicale Universitaire, Lausanne, Switerland
    Hepatogastroenterology 54:729-35. 2007
    ..This study's purpose was to examine the relationship between appropriateness criteria and diagnostic yield of colonoscopy...
  3. doi request reprint Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study
    Jean Jacques Gonvers
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Swiss Med Wkly 140:w13055. 2010
    ..Secondary endpoints were to evaluate predictors of sustained virological response (SVR) and frequency of side-effects...
  4. ncbi request reprint Pregnancy and Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:54-61. 2005
    ..Most drugs, including sulfasalazine, mesalazine, corticosteroids, and immunosuppressors such as azathioprine and 6-mercaptopurine, are safe, whereas methotrexate is contraindicated...
  5. ncbi request reprint Fistulizing Crohn's disease
    Christian Felley
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:26-8. 2005
    ..Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas...
  6. ncbi request reprint Treatment of gastroduodenal Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:37-40. 2005
    ..Presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider...
  7. ncbi request reprint Treatment of postoperative Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:49-53. 2005
    ..Conventional corticosteroids, budesonide or probiotics have no proven role in postoperative prophylaxis. Infliximab has not as yet been studied for use in the prevention of relapse after surgery...
  8. ncbi request reprint Maintenance of remission in Crohn's disease
    Jean Jacques Gonvers
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:41-8. 2005
    ..Patients who responded clinically to infliximab have maintained their clinical response when receiving repeat infusions at 8-week intervals. In patients refractory to other therapies, infliximab may be effective in maintaining remission...
  9. ncbi request reprint Extraintestinal manifestations of Crohn's disease
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:31-6. 2005
    ....
  10. ncbi request reprint Severe and steroid-resistant Crohn's disease
    Pierre Michetti
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:19-25. 2005
    ..Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Nataluzimab may prove useful in patients refractory to infliximab...
  11. ncbi request reprint Therapy of mild to moderate luminal Crohn's disease
    Pierre Michetti
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:13-8. 2005
    ..The role of biological therapies in mild to moderate disease has not been thoroughly evaluated and will not be discussed here...
  12. doi request reprint Maintenance of surgically induced remission of Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:130-5. 2007
    ..Conventional corticosteroids, budesonide or probiotics have no proven role in postoperative prophylaxis. Infliximab has not as yet been studied for use in the prevention of relapse after surgery...
  13. doi request reprint Maintenance of medically induced remission of Crohn's disease
    Jean Jacques Gonvers
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:116-29. 2007
    ..In patients refractory to other therapies, infliximab may be effective in maintaining remission...
  14. doi request reprint Upper gastrointestinal Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:136-40. 2007
    ..The presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider...
  15. doi request reprint Pregnancy and breastfeeding in patients with Crohn's disease
    Christian Mottet
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:149-60. 2007
    ..During breastfeeding, mesalazine and prednisone are considered safe, azathioprine/6-mercaptopurine, budesonide and infliximab probably safe and methotrexate is contraindicated...
  16. doi request reprint Drug safety in Crohn's disease therapy
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:161-8. 2007
    ....
  17. ncbi request reprint Drug safety in the treatment of Crohn's disease
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland
    Digestion 71:8-12. 2005
    ..The safety, dose, duration for optimal efficacy and the most frequent adverse events will be described in this article...
  18. doi request reprint Fistulizing Crohn's disease
    Christian Felley
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:109-12. 2007
    ..Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas...
  19. ncbi request reprint HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin
    Beat Helbling
    Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland
    J Viral Hepat 13:762-9. 2006
    ..013), and treatment was terminated early in 23% and 27% of patients (P = n.s.). The benefit/risk ratio of treating compensated HCV-cirrhotics with STD PEG-IFN/RBV is favourable...
  20. doi request reprint Severe and steroid-resistant Crohn's disease
    Pierre Michetti
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:99-108. 2007
    ..Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Natalizumab may prove useful in patients refractory to infliximab and other anti-TNF agents...
  21. doi request reprint Fibrostenotic Crohn's disease
    Florian Froehlich
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:113-5. 2007
    ..Mechanical treatment methods consist of endoscopic balloon dilation, stricturoplasty or surgical resection. Fibrostenotic Crohn's disease does not respond to medical therapy and requires endoscopic or surgical treatment...
  22. doi request reprint Extraintestinal manifestations of Crohn's disease
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:141-8. 2007
    ....
  23. ncbi request reprint Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial
    Beat Helbling
    Division of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland
    Hepatology 35:447-54. 2002
    ..In conclusion, amantadine does not add to a clinically relevant extent to the treatment of naive patients with chronic hepatitis C...
  24. doi request reprint Mild-to-moderate active luminal Crohn's disease
    Pierre Michetti
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:92-8. 2007
    ..The role of biological therapies has not been thoroughly evaluated in patients with mild disease...
  25. doi request reprint Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort
    Pascal Juillerat
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Scand J Gastroenterol 45:1449-56. 2010
    ..We have applied these criteria retrospectively to the population-based inception cohort of Crohn's disease (CD) patients of the European Collaborative Study Group on Inflammatory Bowel Disease (EC-IBD)...
  26. ncbi request reprint Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness
    Pascal Juillerat
    Department of Gastroenterology and Hepatology, Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Eur J Gastroenterol Hepatol 22:1352-7. 2010
    ..We used data from the Swiss Inflammatory Bowel Disease Cohort Study and predefined appropriateness criteria to examine the appropriateness of use of infliximab (IFX) in CD patients...
  27. ncbi request reprint The EPAGE internet guideline as a decision support tool for determining the appropriateness of colonoscopy
    Olivier Terraz
    Institute for Social and Preventive Medicine, Lausanne, Switzerland
    Digestion 71:72-7. 2005
    ..This study assessed physicians' acceptance ofan Internet-based guideline on the appropriateness of colonoscopy...
  28. ncbi request reprint Development of appropriateness criteria for colonoscopy: comparison between a standardized expert panel and an evidence-based medicine approach
    Anne Nicollier-Fahrni
    Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland
    Int J Qual Health Care 15:15-22. 2003
    ..To assess the degree of agreement between appropriateness criteria for the use of colonoscopy developed by a standardized expert panel method and evidence from published studies...
  29. ncbi request reprint Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection
    Valerie Dutoit
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Eur J Immunol 35:3493-504. 2005
    ..Altogether, these results provide new insights into the characterization of HCV-specific T cell responses in HCV mono-infected and HIV/HCV co-infected individuals...
  30. ncbi request reprint Variations in colonoscopy practice in Europe: a multicentre descriptive study (EPAGE)
    Jennifer K Harris
    Institute for Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland
    Scand J Gastroenterol 42:126-34. 2007
    ..Examination of current practice is important for bench-marking quality. The objective of this study was to examine variations in colonoscopy practice in endoscopy centres internationally...
  31. ncbi request reprint Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II
    Christian Mottet
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Crohns Colitis 3:257-63. 2009
    ....
  32. ncbi request reprint Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II
    Christian Felley
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Crohns Colitis 3:250-6. 2009
    ....
  33. ncbi request reprint Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II
    Pascal Juillerat
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland Healthcare Evaluation Unit, Institute of Social and Preventive Medicine IUMSP, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Crohns Colitis 3:241-9. 2009
    ..The EPACT appropriateness criteria for maintenance treatment after medically-induced remission (MIR) or surgically-induced remission (SIR) of CD thus required updating...
  34. doi request reprint Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication
    Donatella Ciuffreda
    Laboratory of AIDS Immunopathogenesis, Division of Immunology and Allergy, Department of Medicine, CHUV, Lausanne, Switzerland
    Eur J Immunol 38:2665-77. 2008
    ..Therefore, the present results suggest that immune-based mechanisms may contribute to explain the accelerated course of HCV infection in conditions of HIV-1 co-infection and liver transplantation...
  35. ncbi request reprint Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II
    Pierre Michetti
    Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Crohns Colitis 3:232-40. 2009
    ....
  36. doi request reprint EPACT II: project and methods
    Pascal Juillerat
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Digestion 76:84-91. 2007
    ..This chapter describes in detail the process of updating the literature review and the systematic approach of the RAND Appropriateness Method used during the expert panel meeting...
  37. ncbi request reprint Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients
    Alba Muzzi
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 42:41-6. 2005
    ..Liver steatosis is a frequent finding in chronic hepatitis C. An association has been suggested between steatosis and fibrosis progression rate, but the pathogenetic mechanisms linking fatty infiltration and collagen deposition are unknown...
  38. ncbi request reprint Appropriateness of colorectal cancer screening: appraisal of evidence by experts
    Isabelle Peytremann Bridevaux
    Gastroenterology Department, University of Basle, Switzerland
    Int J Qual Health Care 18:177-82. 2006
    ....
  39. ncbi request reprint Endoscope once for any symptom at any age?
    Florian Froehlich
    Gastrointest Endosc 65:358-9; author reply 359. 2007
  40. ncbi request reprint Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C
    Caroline Hora
    Department of Clinical Pharmacology, University of Bern, Bern, Switzerland
    Liver Int 28:370-6. 2008
    ..We hypothesized that CTGF may link steatosis, insulin resistance and fibrosis...
  41. ncbi request reprint Interferon and ribavirin with or without amantadine for interferon non-responders with chronic hepatitis C. A randomized, controlled pilot study
    Christa Wenger
    Gastroenterology and Hepatology, University Hospital Zurich, Switzerland
    Swiss Med Wkly 137:418-23. 2007
    ..Our aim was to compare efficacy and tolerability of an interferon-alfa-2a (INF), ribavirin (RIBA) and amantadine (AMA) combination with those of an INF and RIBA combination...
  42. ncbi request reprint Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C
    Barbara S E August-Jörg
    Division of Gastroenterology, Cantonal Hospital, St Gallen, Switzerland
    Swiss Med Wkly 133:455-60. 2003
    ....
  43. ncbi request reprint Use, appropriateness, and diagnostic yield of screening colonoscopy: an international observational study (EPAGE)
    Bernard Burnand
    Institut Universitaire de Medecine Sociale et Preventive, Rue du Bugnon 17, CH 1005 Lausanne, Switzerland
    Gastrointest Endosc 63:1018-26. 2006
    ..Screening for colorectal cancer (CRC) has been shown to decrease mortality...
  44. ncbi request reprint Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis
    Jean Francois Dufour
    Institute of Clinical Pharmacology, University of Bern, Bern, and Department of Gastroenterology, University Hospital of Lausanne, Switzerland
    Clin Gastroenterol Hepatol 4:1537-43. 2006
    ..UDCA and vitamin E have been considered separately as therapeutic options and have not been shown to be effective. This study tested their combination...
  45. ncbi request reprint Liver allocation in Switzerland
    Francois Mosimann
    Liver Transpl 8:88-9. 2002
  46. ncbi request reprint [Hepatitis C]
    Isabelle Pache
    Division de Gastroentérologie et Hépatologie Prof P Michetti, Centre Hospitalier Universitaire Vaudois CHUV
    Rev Med Suisse Romande 122:507-12. 2002
  47. ncbi request reprint [Quality aspects of digestive system endoscopy]
    Jean Jacques Gonvers
    Rev Med Suisse Romande 122:471-3. 2002
  48. ncbi request reprint Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study
    Florian Froehlich
    Department of Gastroenterology PMU CHUV, Institute of Social and Preventive Medicine, University of Lausanne, Rue du Bugnon 44, CH 1011 Lausanne, Switzerland
    Gastrointest Endosc 61:378-84. 2005
    ..Therefore, this study assessed the factors that determine colon-cleansing quality and the impact of cleansing quality on the technical performance and diagnostic yield of colonoscopy...